IRB #

STUDY00020010

Title

Early Access Program (EAP) for avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Principal Investigator

Michael Heinrich

Study Purpose

This Expanded Access Program is intended to provide access to avapritinib treatment for patients with locally advanced unresectable or metastatic GIST. Additionally, it aims to further characterize the safety and effectiveness of avapritinib.

Medical Condition(s)

GIST that carries a mutation in exon 18 of the PDGFRA gene

Eligibility Criteria

1. Patients 18 years and older
2. Patients with GIST that cannot be removed surgically and are not eligible for an ongoing study of avapritinib

Other eligibility criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

No minimum or maximum treatment duration has been set. Patients will be monitored at regular intervals for safety and for response to treatment.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Blueprint Medicines Corporation

Recruitment End

05/31/2023

Compensation Provided

No


Go Back